Important Dates

no event

Latest News

Novartis Global study endorsed* by EHDN

Study aims and goal: A Randomized, double-blind, placebo-controlled dose range finding study with Open-Label Extension to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LMI070/branaplam in participants with early manifest HD. No. of study sites: This Phase IIb study aims to recruit stage 1 and 2 participants at sites in Belgium, Canada, France, Germany, Hungary, […]

Read More…

EHDN Newsletter – 43rd edition

The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]

Read More…

Join us at the EHDN 2021 Remote Meeting

Dear Friend of EHDN, On behalf of the members of the Program and Organizing Committee and the Executive Committee of the European Huntington´s Disease Network it is our pleasure to cordially invite you to attend the 3 half-day EHDN Remote Meeting on Thursday – Saturday, September 9-11, 2021. […]

Read More…